secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theriva Biologics, Inc. (TOVX)
CIK:        0000894158
Form:       8-K
Filed at:   2026-08-06T12:10:35+00:00
Accession:  0001104659-26-091674
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theriva Biologics doses first patient in VIRAGE2 Phase 2a trial of VCN-01 in metastatic PDAC
--------------------------------------------------------------------------------

- First patient dosed in VIRAGE2 Phase 2a trial evaluating more frequent repeated dosing of VCN-01 in first-line metastatic PDAC.
- Enrollment completion expected H2 2026; initial pharmacodynamic and safety/tolerability data anticipated by Q3 2027.
- Trial based on VIRAGE Phase 2b data where 2 doses of VCN-01 + SoC showed improved overall survival, progression-free survival, and duration of response vs SoC alone.
- EMA and FDA feedback recognized potential of repeated VCN-01 dosing to improve clinical outcomes.
- Results will inform dosing regimen for potential future pivotal Phase 3 trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/894158/000110465926091674/0001104659-26-091674-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/894158/000110465926091674/tm2622359d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-091674

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer